⭐️Leading Causes of Death in the US, 2019-2023. Interesting how the #healthcare landscape has changed in 4 yrs. Cancer remains the 2nd leading cause of death after heart disease JAMA Oncology JAMA OncoDaily jamanetwork.com/journals/jama/…

Clinical Outcomes and Histologic Findings of pts With HCC With Durable Partial Response or Durable Stable Disease After Atezolizumab + Bevacizumab Journal of Clinical Oncology doi.org/10.1200/JCO.24… 🔎Imbrave150 & RWD 👉favorable PFS & OS + high rates of pCR in pts w/ PR for ≥6 mo ESMO - Eur. Oncology

Distinct clinical outcomes & biological features of specific KRAS mutants in human pancreatic cancer Cancer Cell doi.org/10.1016/j.ccel… 👉KRASG12R enriched in early stage w/ reduced nodal disease + distant recurrence 👉improved OS 🧐 Supports KRAS mutational testing in #PDAC

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies & for steering drug development Annals of Oncology doi.org/10.1016/j.anno… 👏Excellent concept ESMO - Eur. Oncology

📢Hepatopancreaticobiliary-NET abstracts in #ESMO24 ESMO - Eur. Oncology ➡️HCC ✅LBA3 - Transarterial Chemoembolization (TACE) With or Without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase 3 LEAP-012 Study ✅LBA38 - Iparomlimab and

Trastuzumab deruxtecan in HER2+ advanced mCRC The Lancet Oncology doi.org/10.1016/S1470-… 🔎DESTINY-CRC02 phs 2, 122 pts 👉5·4 & 6·4 mg/kg 👉ORR 37·8% & 27·5% 👉mPFS 5·8 & 5·5 mo 👉mOS 13·4 mo & NE 🧐support approval for pts with HER2-positive solid tumours ESMO - Eur. Oncology

Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression: Cancer Cell cell.com/cancer-cell/fu…

Thank you Google Maps and Apple #Maps for completely ignoring a 50-min delay caused by a car crash and not suggesting the fastest route. It will take 3 hours instead of 2. Totally unreliable 😡

L’Italia chiude questa giornata con un’altra fantastica medaglia d’oro ai #GiochiParalimpici 🇮🇹 Nel lancio del disco Rigivan Ganeshamoorthy migliora per ben tre volte il record del mondo, 27.06 metri, con oltre 6 metri di distacco sul secondo classificato 👏🏼

Alternating gemcitabine/nab-paclitaxel and gemcitabine vs continuous gemcitabine/nab-paclitaxel after induction Tx of #PDAC The Lancet Oncology doi.org/10.1016/S2468-… 🔎 ALPACA phs 2, 325 pts 👉Similar OS, but improved tolerability 🧐Alternating schedule may be considered ESMO - Eur. Oncology

📘Current and future treatments of biliary tract cancers ESMO - Eur. Oncology-Gastrointestinal Oncology Journal 👉doi.org/10.1016/j.esmo… Florian Lordick Ben Westphalen Hanneke van Laarhoven Teresa Macarulla OncoAlert #cancer #oncology #MedX

Meet the BTC Team! 🌍 Meet Dr Angela Lamarca Angela Lamarca, medical oncologist finding new treatment options for patients with BTC, and Savino Paradiso Sapienza Università di Roma, PhD student at Sapienza University researching targeted therapies for iCCA 💡 🔗 precision-btc.eu/news-meetbtc

Il bellissimo sorriso di Rigivan Ganeshamoorthy ricevendo la medaglia d’oro nel lancio del disco ai #GiochiParalimpici, ottenuta migliorando per ben tre volte il record del mondo durante la gara 👏🏼

A how to for multidisciplinary clinics in hepatology doi.org/10.1097/hep.00… in HEPATOLOGY Journal Anjana Pillai

Thank you for the shout out Elliot Tapper -something I’ve been wanting to write up for some time and just needed to find the right people to weigh in with their expertise! Liver/Intestinal Community of Practice - AST HEPATOLOGY Journal

Fell short in today's match, but it’s always a privilege to play in the @USOpen. NYC has a special place in my heart. Grateful for all the support and to everyone who makes this event happen. 🙏🎾

🔍 Discover How: Dive into the latest IO-based strategies 🎯 for HCC & BTC at our event. Master patient selection 🔬 for embolization and seamlessly integrate immunotherapy with a multidisciplinary approach. 👉 ms.spr.ly/6016m8Hxr 👥: Arndt Vogel Lorenza Rimassa 📍 #ESMO24

🔍 Discover How: Dive into the latest IO-based strategies 🎯 for HCC & BTC at our event. Master patient selection 🔬 for embolization and seamlessly integrate immunotherapy with a multidisciplinary approach. 👉 ms.spr.ly/6018m8HAg 👥: Arndt Vogel Lorenza Rimassa 📍 #ESMO24

Please register for the Medscape symposium on #Immunotherapy for #hepatobiliary cancer #HCC #BTC #CCA at #ESMO24! Stephen L. Chan Arndt Vogel #BrunoSangro Humanitas University Humanitas Milano

Please register for the MedscapeLIVE symposium on #Immunotherapy for #hepatobiliary cancer #HCC #BTC #CCA at #ESMO24! Stephen L. Chan Arndt Vogel #BrunoSangro Humanitas University Humanitas Milano